Exciting Developments in ADC Technology from Clinical Trials

Recent Breakthroughs in ADC Candidates at the ASCO Annual Meeting

The ASCO Annual Meeting showcased promising clinical data from Duality Bio, presenting new developments in ADC candidates. These advancements signal hope for patients battling advanced cancers. Duality Bio (HKEX: 9606.HK) brought to light findings from two significant trials involving their B7H3 ADC candidate, DB-1311/BNT324, and HER3 ADC candidate, DB-1310.

B7H3 ADC Candidate DB-1311/BNT324 Performance

In an exciting oral session, the data regarding the B7H3-targeted ADC candidate DB-1311/BNT324 was revealed. This ongoing Phase 1/2 trial focuses on patients with heavily pre-treated castration-resistant prostate cancer (CRPC). The preliminary results indicate a notable early clinical activity alongside a manageable safety profile, with minimal discontinuation rates.

Among the 52 patients who were evaluated for efficacy, the confirmed objective response rate (cORR) stood at 30.8%, with an impressive disease control rate (DCR) of 90.4%. Moreover, the study reported a 6-month rate of radiographic progression-free survival (rPFS) at 69.8% among 68 evaluable patients. Encouragingly, these outcomes were consistent across the various dosage levels (6 mg/kg and 9 mg/kg). Patients who underwent earlier treatment lines demonstrated better results, showing significant anti-tumor activity even in post-treatment lines.

The clinical trial is currently enrolling new patients, including those who are taxane-naïve and those who have undergone Lu-177 treatment, presenting an opportunity for further promising results.

Addressing the Unmet Need in Prostate Cancer

Given the rising incidence of prostate cancer, the need for effective therapies has never been more crucial. The DB-1311/BNT324 program has received Fast Track Designation from the U.S. Food and Drug Administration (FDA), signifying its potential in treating patients with advanced or metastatic CRPC that has not responded to standard treatments.

HER3 ADC Candidate DB-1310 Offers Encouraging Results

In addition, the presentation of DB-1310, a HER3 ADC candidate, demonstrated encouraging outcomes in patients with advanced solid tumors who have not found success with standard treatment protocols. Results from the first-in-human Phase I/IIa study highlighted a 31% unconfirmed objective response rate (uORR) among 123 patients, with a disease control rate (DCR) reaching 84%.

Notable results emerged from patients specifically diagnosed with EGFR-mutated non-small cell lung cancer (NSCLC), where the uORR reached 44% and DCR stood at 91%. The findings also showcased that patients received a median progression-free survival (mPFS) of 7 months, with a median overall survival (mOS) of 18.9 months, particularly impressive at a 5.5 mg/kg Q3W dose, where the uORR peaked at 66.7%.

DB-1310 has exhibited a well-tolerated safety profile, with the most frequent treatment-related adverse events being mild digestive and hematological issues, resulting in a low treatment-related discontinuation rate of just 3.5%. These promising results further endorse the development of DB-1310, both as a standalone treatment and in combination therapies with existing regimens such as EGFR TKIs and HER2-targeted therapies.

The Vision of Duality Bio

Duality Bio is dedicated to advancing ADC technology and therapies aimed at treating cancer and autoimmune conditions. With a strong commitment to innovation, the company has developed several ADC platforms protected by global intellectual property rights. Their robust pipeline is further supplemented by strategic collaborations with leading biotech innovators and global corporations.

Dedicating resources across 17 countries, Duality Bio has actively engaged in multiple clinical trials, enrolling more than 2,000 patients for a range of clinical-stage ADC candidates. As a global leader in ADC technology, the company remains focused on developing bispecific ADCs, novel payload structures, and specialized treatments for autoimmune diseases.

Frequently Asked Questions

What were the recent advancements presented by Duality Bio?

Duality Bio presented preliminary clinical trial results for their ADC candidates, demonstrating promise for patients with advanced cancers.

What is the B7H3 ADC candidate DB-1311/BNT324?

This candidate targets B7H3 and aims to treat heavily pre-treated castration-resistant prostate cancer with promising efficacy and safety results.

What results were highlighted for the HER3 ADC candidate DB-1310?

DB-1310 showed a 31% unconfirmed response rate in advanced solid tumors and great efficacy in patients with EGFR-mutated non-small cell lung cancer.

How is Duality Bio positioned in the ADC landscape?

Duality Bio is a leader in ADC technology development, with a strong pipeline and numerous strategic collaborations globally.

What does Fast Track Designation signify for DB-1311/BNT324?

This designation indicates a significant potential for this treatment to address unmet needs in prostate cancer therapies, expediting its development.

About The Author

Hi there, As a writer and financial specialist, Henry Turner is passionate about guiding people through the complex world of finance. Having worked in finance for many years, I am an expert at simplifying difficult financial ideas into understandable, useful insights for my blog and articles. My goal is to arm you with the confidence and information you need to make wise financial choices.

Writing for a number of financial blogs has allowed me to interact with readers from novice investors looking for fresh ideas to seasoned investors starting their financial journeys. My mission is to enable everyone to understand and access finance, so enabling you to confidently and clearly reach your financial goals. I appreciate you traveling with me toward success and financial literacy.

Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.